Immunoglobulin A Nephropathy (Otsuka Pharmaceutical Development & Commercialization, Inc.)
Protocol Name: Otsuka Pharmaceutical Development & Commercialization, Inc. / “A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy” Indication: Immunoglobulin A Nephropathy Primary Investigator: Dr. Bernard Fischbach Location: Landry Office – 411 N. Washington Avenue, Suite 6000, Dallas, TX 75246 DETAILS >